Abstract Spinocerebellar ataxia type 14 (SCA14) is an autosomal dominant neurodegenerative disorder, first described in a Japanese family, showing linkage to chromosome 19q13.4-qter. Recently, mutations have been identified in the PRKCG gene in families with SCA14. The PRKCG gene encodes the protein kinase Cc (PKCc), a member of a serine/threonine kinase family involved in signal transduction important for several cellular processes, including cell proliferation and synaptic transmission. To identify the disease-causing mutation in a large group of ataxia patients, we searched for mutations in the PRKCG gene. We ascertained 366 unrelated patients with spinocerebellar ataxia, either pure or with associated features such as epilepsy, mental retardation, seizures, paraplegia, and tremor. A C-to-G transversion in exon 4, resulting in a histidine-to-glutamine change at codon 101 of the PKCc protein, was identified in patients from a family with slowly progressive pure cerebellar ataxia. Functional studies performed in HEK293 cells transfected with normal or mutant construct showed that this mutation affects PKCc stability or solubility, verified by time-dependent decreased protein levels in cell culture. In conclusion, the H101Q mutation causes slowly progressive uncomplicated ataxia by interfering with PKCc stability or solubility, which consequently may cause in either case a decrease in the overall PKCc-dependent phosphorylation.
Introduction
The spinocerebellar ataxias (SCAs) are a clinically and genetically highly heterogeneous group of inherited neurodegenerative disorders. They are characterized by progressive motor incoordination affecting the limbs and gait and are associated with degeneration of cerebellar Purkinje cells and brainstem neurons. Eleven SCA-associated genes have been identified to date, allowing the classification of these SCAs according to genotype and pathogenic mechanism (Schols et al. 2004 ). In SCA1, 2, Machado-Joseph disease (MJD/ SCA3), 6, 7, 17, and dentatorubropallidoluysian atrophy (DRPLA), an expansion of a CAG repeat located within the coding region of the disease gene gives rise to an expanded polyglutamine tract in the disease protein. In SCA8, 10, and 12, the mutation consists in a tri-or pentanucleotide repeat expansion in a noncoding region. Alterations in amino acid composition, conducting to a deregulation in protein function, have been found to be responsible for cerebellar ataxia in SCA6, SCA14, and FGF14-related cerebellar ataxia (Schols et al. 2004) .
Spinocerebellar ataxia type 14 (SCA14; MIM 605361) is an autosomal dominant disorder, first described in a three-generation Japanese family, showing linkage to chromosome 19q13.4-qter. The disease in this family was characterized by pure cerebellar ataxia or by intermittent axial myoclonus, followed by ataxia, in earlyonset cases (Yamashita et al. 2000) . Brkanac et al. (2002) described a SCA family of English and Dutch descent whose disease also showed linkage to the same region of chromosome 19. A missense mutation in the PRKCG gene was identified in patients from this family, all presenting pure cerebellar ataxia without myoclonus . A Q127R change in protein kinase Cc (PKCc), encoded by the PRKCG gene, has been found as the causative mutation in the Japanese family first showing linkage to this locus (Yabe et al. 2003) . All of these mutations are in the regulatory domain of PKCc (Fig. 1) . The first mutation in the catalytic domain, F643L, was reported in a French family with cerebellar ataxia, myoclonus, and cognitive impairment (Stevanin et al. 2004) . To date, a total of 11 mutations have been found in the PRKCG gene, seven of them in exon 4 (Chen et al. 2005) .
PKCc is a member of a serine/threonine kinase family (Coussens et al. 1986; Knopf et al. 1986 ) involved in signal transduction relevant to several cellular processes, including cell proliferation and synaptic transmission (Tanaka and Nishizuka 1994; Zeidman et al. 1999) . All PKCs have an amino-terminal regulatory domain as well as a carboxyl-terminal catalytic domain. They are grouped in three subclasses based on the composition of the regulatory domain (Mellor and Parker 1998) . The two basic blocks of the regulatory domain, for conventional and novel PKCs, are C1 and C2, which are diacylglycerol and calcium sensors, respectively (Newton 2003) , whereas the catalytic domain encloses kinase and substrate-recognition regions (Fig. 1) .
Herein we report a Portuguese family with SCA14 presenting a mutation located in a highly conserved residue of the Cys 2 cystein-rich region of the amino-terminal regulatory domain, which causes downregulation of PKCc.
Patients and methods

Subjects
We studied a total of 366 unrelated patients presenting SCA with or without associated symptoms such as epilepsy, mental retardation, seizures, paraplegia, and tremor. Among these patients, 103 represented families with apparently autosomal dominant inheritance, 41 were from families with patients in only one generation, and 222 were isolated cases; 325 unrelated affected subjects were of Portuguese origin, whereas 41 families were from Brazil. Repeat expansions responsible for SCA1, SCA2, MJD, SCA6, SCA7, SCA8, SCA10, SCA12, SCA17, and DRPLA were previously excluded in each of these 366 families (unpublished results).
Methods
Mutation analysis
Peripheral blood was collected from patients and their relatives after written informed consent was obtained. Genomic DNA was obtained from peripheral blood leukocytes by standard techniques (Sambrook et al. 1989 ).
Molecular analysis of exon 4 was performed by PCR amplification using the primers exon 4 forward (aaaagataaaagggcccctc) and reverse (aacccagaccgggcgctttg) (239 bp) and carried out with PCR conditions described elsewhere (Alonso et al. 2003) . PCR products of exon 4 and intronic boundaries were screened for molecular (Chen et al. , 2005 van de Warrenburg et al. 2003; Yabe et al. 2003; Stevanin et al. 2004; Verbeek et al. 2005) variants by SSCP analysis (Orita et al. 1989 ). Electrophoresis was carried out in 15% polyacrylamide gels at 15°C. Conformational changes were confirmed by direct and reverse sequencing with BigDye Terminator Cycle Sequencing v1.1 Ready Reaction (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions, and samples were analyzed on a 310 ABI PRISM genetic analyzer (Applied Biosystems).
cDNA constructs and site-directed mutagenesis
The human PRKCG full-length cDNA cloned in the pcDNA3/Amp vector was generously provided by Dr. S.M. Prescott (University of Utah). The C-to-G transversion found at the 303 position was introduced into the PRKCG cDNA using the QuickChange Site-Directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. The single base change was introduced using the following sense MDc303g-F (ccccggaacaaacagaagttccgcctgcatag) and antisense MDc303g-R (ctatgcaggcggaacttctgtttgttccgggg) oligonucleotides, which contained the mutant base. Successful mutagenesis was confirmed by sequencing normal and mutated constructs entirely (2,094 bp).
Cell culture and transfection
The HEK293 cells were propagated under standard conditions using Dulbecco's modified Eagle's medium with L-glutamine and 4,500 mg/l glucose and supplemented with 3.7 g/l sodium bicarbonate and 10% fetal bovine serum (Sigma, St. Louis, MO, USA). HEK293 cells were plated in 60-mm dishes. Cells were transfected with 5 lg of each expression vector encoding wild type (H101), mutant (Q101) PKCc, or pcDNA3/Amp empty vector. All transfections were performed using the calcium phosphate precipitation method. Expression of the target protein was allowed for 36, 48, or 72 h.
RT-PCR
RNA extraction was performed with Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. RNA concentration was determined by spectrophotometry, and complementary DNA (cDNA) was generated from equal amounts of total RNA using ready-to-go RT-PCR beads (Amersham BioSciences, Piscataway, NJ, USA) according to the manufacturer's instructions. Semiquantitative PCR was performed using, simultaneously, primers PKCc-F (ccttctgcgaccactgt) and PKCc-R (gctgcagttgtcagcat) (557 bp) to detect PKCc, and ACTB-F (cgtcttcccctccatcgt) and ACTB-R (gcgcaagttaggttttgt) (1,096 bp) to detect b-actin, used as internal control. PCR was performed using the long template PCR system (Roche, Basel, Switzerland) under the manufacturer's conditions: 0.15 lM of PKCc-F and PKCc-R primers, 1.5 lM of ACTB-F and ACTB-R primers, 350 lM dNTPs, expand long template system buffer 1 (17.5 mM Fig. 2 Pedigree of the family described, SSCP analysis, and sequencing of exon 4. a Black circles and squares indicate affected individuals with progressive cerebellar ataxia; a gray symbol indicates a subject referring no complaints but with abnormal signs on neurological exam; a dot in a symbol indicates an unaffected carrier. Patient IV9 refused to provide a sample for molecular analysis. Also shown are the disease ages at onset. PCR products were analyzed on 15% polyacrylamide gels by SSCP. A three-band pattern was detected in all patients with DNA available. b Sequencing of exon 4 in control and patient. A Cto-G substitution was detected at position 303, causing a histidine-to-glutamine change within the Cys 2 cystein-rich region of the PKCc MgCl 2 ), and 4 U of expand long template enzyme mix, in a final volume of 50 ll; the PCR conditions consisted of an initial denaturing step at 95°C for 5 min, 30 cycles (95°C for 45 s, 55°C for 45 s, and 72°C for 1 min), and a final extension at 72°C for 5 min. Under these conditions, the exponential phase was determined for both genes, simultaneously, by PCR products accumulation at a constant rate. b-actin was also validated as an internal control, with a constant expression level across the different samples analyzed. Band quantifications were performed on the GS-800 calibrated imaging densitometer from Bio-Rad (Hercules, CA, USA).
Protein expression
Protein extraction was performed with RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, 5 mM EGTA, 1% triton, 0.5% DOC, 0.1% SDS, pH 7.5) supplemented with phosphatase inhibitors (50 mM NaF, 1 mM Na 3 VO 4 and 10 mM Na 4 PO 7 ) in the presence of protease inhibitors (Roche).
Protein concentrations were determined using the Bio-Rad Dc (Hercules) assay according to the manufacturer's protocol. Equal amounts (30 lg) of protein were loaded onto a 10% denaturing polyacrylamide gel and transferred to nitrocellulose membranes. Membranes were probed with anti-PKCc (Transduction Laboratories, San Jose, CA, USA) and anti-b-actin, used as internal control (Sigma). The immunoreactive bands were visualized by the ECL Western blot detection kit (Amersham BioSciences). Band quantifications were performed on the GS-800 calibrated imaging densitometer from Bio-Rad (Hercules).
Statistical analysis
All quantitative data are expressed as mean ± SD of three independent experiments. Comparison of expression levels between wild type and mutant protein or mRNA was carried out using Student's unpaired t-test.
Results
Mutation analysis
In one large Portuguese family, mutation detection revealed a mobility variant in exon 4, showing a threeband pattern (Fig. 2a) . In the proband of this family, a C-to-G heterozygous transversion in nucleotide 303 of the ORF (GenBank accession number NM_002739) was detected by sequencing (Fig. 2b) . This substitution produces a histidine-to-glutamine change at codon 101 of the PKCc. Amino acid sequence alignment showed conservation of this His101 in the Cys 2 region among PKCc isozymes from species such as M. musculus, R. norvegicus, O. cuniculus, B. taurus, D. melanogaster, and C. elegans, as well as in other human PKC isozymes (Fig. 3) . Mutation analysis by SSCP did not detect this base change in 400 control chromosomes from the Portuguese population. All subjects from this family with DNA available were analyzed for the presence of this mutation (Fig. 2a) . The mutation cosegregated with the disease in another affected individual (III10). Two asymptomatic at-risk subjects, aged 26 and 25, one with minor neurological signs, also inherited the mutation. Screening of exon 4, where the majority of SCA14 
Clinical findings
This family was characterized by pure cerebellar ataxia, with disease onset during or after the third decade and a benign course in the first two generations. In the younger generation the onset was earlier, in their 20s, and the clinical expression was also more severe. The proband of this family (III9), aged 65, had shown slowly progressive gait ataxia since the age of 30, followed by increasing difficulties in speaking and writing, and dysphagia by the age of 45. At examination, she presented moderate cerebellar dysarthria, dysphonia, bilateral horizontal nystagmus, limb dysmetria that was more severe in the lower limbs, and slight truncal and severe gait ataxia; no other neurological abnormalities were present. Her father (II3), who died at the age of 85 years, was said to have had gait imbalance since his fourth decade and to have been slightly dysarthric, as well having needed unilateral help walking in his later years. The only living affected brother of the proband (III10), aged 63, had gait ataxia with onset by the age of 30. His disease state had progressed slowly, with dysarthria by the age of 50 and dysphagia 10 years later. He was still able to walk unaided when he was last examined at age 63. Horizontal nystagmus and limb dysmetria were also observed at neurological examination. The proband's niece (IV9), aged 35, first experienced unstable gait by the age of 26 years, followed by dysarthria 2 years later. She also had horizontal nystagmus and limb dysmetria. Although she was still able to walk without help for short distances, her neurological condition was clearly worse than her father's. One of her siblings (IV10), still in his 20s, referred no complaints related to the disease, but he had horizontal nystagmus and slight heel-to-knee dysmetria and was unable to perform tandem walking.
Neuroimaging studies
Brain magnetic resonance imaging of the proband showed severe atrophy of the cerebellum, especially in the anterior part of the cerebellar hemispheres and in the superior vermis, as well as cerebral cortical atrophy (Fig. 4) .
Functional studies
To investigate the influence of the H101Q mutation in PKCc turnover, we compared PKCc expression levels in HEK293 cells transfected with normal and mutant PKCc. The levels of normal and mutant PRKCG mRNA did not significantly differ, showing that regulation of transcription is not altered and that transfection efficiencies were equal for normal and mutated constructs (Fig. 5a) . A decrease in the expression level of the mutant protein was observed under the used conditions when compared with the normal. This effect increased with the time in culture after transfection, with a drop of 25%, 40%, and 60% at 36, 48, and 72 h of culture, respectively (Fig. 5b) . These results were reproducible in three independent experiments.
Discussion
In this study, we describe a new mutation in PKCc, H101Q, causing SCA14 due to protein loss. By mutation analysis, we identified a new H101Q mutation in all available patients from a family with pure spinocerebellar ataxia. This mutation was not present in 400 control chromosomes. HEK293 cells expressing the mutant form of PKCc (Q101) showed reduced PKCc protein levels compared with normal PKCc (H101). Although equal amounts of normal and mutant PRKCG mRNA were observed, reduction in mutant protein levels occurred with culture time, indicating that the mutant protein is putatively targeted for degradation at a higher rate. Alternatively, this result may be an indirect finding reflecting the protein insolubility or removal into cytoplasmic aggregates, as a previous report has shown that mutant PKCc-GFP proteins readily aggregated in the cytoplasm, leading to cell death (Seki et al. 2005) .
The PKCc protein is composed of an amino-terminal regulatory domain and a carboxyl-terminal catalytic domain. The regulatory domain has two cystein-rich C1 domains (Cys 1 and Cys 2), each of which interacts with two zinc ions and makes available high-affinity binding sites for diacylglycerol and phorbol esters. The mutation H101Q, located in the Cys 2 cystein-rich region, replaces a residue critical for both zinc coordination and phorbol ester-binding ( Fig. 1; Quest et al. 1994) . Solution-structure modeling for a protein with a mutation that also replaces this residue, H101Y, showed that its conformation fluctuated widely, especially in the Zn1 and phorbol ester-binding sites . Our results show that a mutation at position H101 can interfere directly with protein function by affecting protein stability and probably by changing Zn 2+ interaction and phorbol ester-binding, which may lead to loss of protein kinase activity. Two other mutations, G118D and C150F, also located on the regulatory domain of PKCc, cause an increase in PKCc kinase activity (Verbeek et al. 2005) . Together with our results, this suggests that the mechanism underling SCA14 pathogenesis is triggered by changes in regulation of PKCc. The altered phosphorylation of PKCc substrates may be the first step in the disease mechanism, which is probably due to abnormalities in the innervation of Purkinje cells by climbing fibers, as observed in PKCc knockout mice, which also suffer from abnormal gait and incoordination (Chen et al. 1995) . It is thought that PKCc is important in synaptic formation but not in early neuronal development; therefore, alterations in synaptic formation of Purkinje cells, caused by persistent multiple innervation of these cells by climbing fibers, may play an important role in disease associated with the H101Q mutation, as described here.
In this family, disease onset was during or after the third decade, with gait ataxia that progressed slowly and became associated with other cerebellar signs, such as dysphagia and dysarthria. The disease had a benign course in the first two generations but had an earlier onset in the youngest generation, with a more severe clinical expression. In the first family linked to the SCA14 locus (Yamashita et al. 2000) , some patients presented cerebellar ataxia in the third decade of life, whereas those with an earlier onset began with myoclonus and only later developed cerebellar ataxia. The first families reported with PKCc mutations in the regulatory domain had slowly progressive, uncomplicated cerebellar ataxia that began in the third or fourth decade of life, whereas patients with PKCc mutations in the catalytic domain present a broader age at onset, ranging from childhood to the sixth decade of life (van de Warrenburg et al. 2003; Yabe et al. 2003; Stevanin et al. 2004; Chen et al. 2005) .
The fact that SCA14 is an autosomal dominant disease suggests a pathogenetic mechanism based on gain of function of mutant proteins. Though immunohistochemical studies showed that Purkinje cells from a patient with H101Y stained very poorly for PKCc , this together with the fact that aggregated PKCc seems to be inactive (Seki et al. 2005 ) strongly supports a reduction of PKCc in the etiology of SCA14. In this case, the mutant proteins could have a dominant negative effect by perhaps competing with the wild-type protein for substrate binding. The first disease-causing mutations identified in SCA genes were unstable tri-or pentanucleotide repeats, within coding or noncoding regions, that could lead to abnormalities in protein conformation or expression. The newly identified point mutations in PKCc unveil a new perspective for understanding mutation effects on protein function and shedding light on the cellular pathways implicated in these diseases.
In conclusion, this new H101Q mutation, located on the Cys 2 cystein-rich region of protein kinase Cc, causes a pure spinocerebellar ataxia, probably by interfering with protein stability or protein solubility, which in either case may lead to a decrease in the overall cell serine/ threonine phosphorylation level.
